Carbonic anhydrase IX expression is associated with tumor progression and a poor prognosis of lung adenocarcinoma

Lung Cancer ◽  
2006 ◽  
Vol 54 (3) ◽  
pp. 409-418 ◽  
Author(s):  
Hidehiro Kon-no ◽  
Genichiro Ishii ◽  
Kanji Nagai ◽  
Junji Yoshida ◽  
Mitsuyo Nishimura ◽  
...  
2004 ◽  
Vol 10 (13) ◽  
pp. 4464-4471 ◽  
Author(s):  
Kårstein Måseide ◽  
Rita A. Kandel ◽  
Robert S. Bell ◽  
Charles N. Catton ◽  
Brian O’Sullivan ◽  
...  

Cancer ◽  
2009 ◽  
Vol 115 (12) ◽  
pp. 2732-2743 ◽  
Author(s):  
Masayuki Nakao ◽  
Genichiro Ishii ◽  
Kanji Nagai ◽  
Akikazu Kawase ◽  
Hirotsugu Kenmotsu ◽  
...  

2018 ◽  
Vol Volume 11 ◽  
pp. 6879-6886 ◽  
Author(s):  
Kazuma Okuno ◽  
Takao Matsubara ◽  
Tomoki Nakamura ◽  
Takahiro Iino ◽  
Takuya Kakimoto ◽  
...  

2019 ◽  
Vol 86 ◽  
pp. 233-242 ◽  
Author(s):  
Yixuan Wang ◽  
Junjie Piao ◽  
Qianrong Wang ◽  
Xuelian Cui ◽  
Ziqi Meng ◽  
...  

2010 ◽  
Vol 456 (5) ◽  
pp. 483-490 ◽  
Author(s):  
Matthias Choschzick ◽  
Linn Woelber ◽  
Stephan Hess ◽  
Christine zu Eulenburg ◽  
Jörg Schwarz ◽  
...  

2021 ◽  
pp. jclinpath-2020-207073
Author(s):  
Alessandro Pietro Aldera ◽  
Dhirendra Govender

Carbonic anhydrase IX (CAIX) is a transmembrane metalloenzyme which is upregulated in tumour cells under hypoxic conditions. CAIX expression is induced by the accumulation of hypoxia-inducible factor-1α and has several downstream effects, including acidification of the extracellular pH, loss of cellular adhesion and increased tumour cell migration. CAIX is upregulated in a variety of solid organ tumours and has prognostic implications. High CAIX protein expression is a marker of poor prognosis in breast, lung, ovarian and bladder carcinomas. Conversely, low expression is an indicator of poor prognosis in clear cell renal cell carcinoma (CCRCC). CAIX immunohistochemistry is useful diagnostically to identify metastatic CCRCC, and the recently recognised clear cell papillary renal cell carcinoma. There is much interest in targeting CAIX with monoclonal antibodies and small molecule inhibitors. There are several small molecule inhibitors under development which have shown promising results in clinical trials. In this paper, we provide an overview of the role of CAIX in tumourigenesis and outline its use as a prognostic, diagnostic and therapeutic biomarker.


Sign in / Sign up

Export Citation Format

Share Document